CSF1R and neoplasm: Use of the CSF1-R inhibitor PLX3397 as single agent in patients with recurrent GBM showed no improvement in survival (153), however, combination studies in preclinical models of melanoma demonstrated improvement of adoptive cell therapy, accompanied by reduction of tumor-infiltrating TAM and MDSC and augmentation of IFN-γ-secreting TILs (154), advocating for its use in combination therapies in humans.